ReviewCurrent HIV/AIDS reports2012
HIV reservoirs and strategies for eradication.
Review in Current HIV/AIDS reports, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed.
- Peripheral T Follicular Helper Cells Are the Major HIV Reservoir within Central Memory CD4 T Cells in Peripheral Blood from Chronically HIV-Infected Individuals on Combination Antiretroviral Therapy.Journal of virology · 2015Trial
- Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy.PLoS pathogens · 2014Trial
- Provirus activation plus CD59 blockage triggers antibody-dependent complement-mediated lysis of latently HIV-1-infected cells.Journal of immunology (Baltimore, Md. : 1950) · 2014Trial
- Antigen Presenting Cell-Mediated HIV-1Medical research archives · 2023Article
- No evidence of neuronal damage as measured by neurofilament light chain in a HIV cure study utilising a kick-and-kill approach.Journal of virus eradication · 2021Article
- Stem cell-derived CAR T cells traffic to HIV reservoirs in macaques.JCI insight · 2021Article
- The Potential Contribution of Caveolin 1 to HIV Latent Infection.Pathogens (Basel, Switzerland) · 2020Review
- Association of Viral Persistence and Atherosclerosis in Adults With Treated HIV Infection.JAMA network open · 2020Article
- Antiretroviral Penetration and Drug Transporter Concentrations in the Spleens of Three Preclinical Animal Models and Humans.Antimicrobial agents and chemotherapy · 2020Article
- HIV persists throughout deep tissues with repopulation from multiple anatomical sources.The Journal of clinical investigation · 2020Article
- [Public health and eradication of infection by the Human Immunodeficiency Virus].Revista espanola de salud publica · 2019Article
- Ephedrine enhances HIV-1 reactivation from latency through elevating tumor necrosis factor receptor II (TNFRII) expression.Heliyon · 2019Article
- Crossroads of Cancer and HIV-1: Pathways to a Cure for HIV.Frontiers in immunology · 2019Review
- HIV 2-LTR experiment design optimization.PloS one · 2018Article
- Multimodal analysis of drug transporter expression in gastrointestinal tissue.AIDS (London, England) · 2017Article
- Review
- Antiretroviral drug transporters and metabolic enzymes in human testicular tissue: potential contribution to HIV-1 sanctuary site.The Journal of antimicrobial chemotherapy · 2016Article
- Comorbidities associated with HIV and antiretroviral therapy (clinical sciences): a workshop report.Oral diseases · 2016Article
- Defective iron homeostasis in human immunodeficiency virus type-1 latency.Current trends in immunology · 2016Article
- Immuno-modulatory strategies for reduction of HIV reservoir cells.Journal of theoretical biology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Combination antiretroviral therapy (cART) has led to a reduction in morbidity and mortality in HIV-infected patients but therapy is lifelong and there is no cure for HIV. The major barriers to cure include HIV latency, which has been identified in different T-cell subsets, as well as persistence of HIV in anatomical reservoirs. We review recent developments in our understanding of the major reservoirs of HIV in patients on cART as well as how latency is established and maintained in T cells. Finally, we review the scientific rationale of and clinical experience with pharmacotherapeutic strategies aimed at eliminating latently infected cells.
Indexed as
Identifiers
22249405What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.